var data={"title":"Mitoxantrone: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Mitoxantrone: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6596?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=mitoxantrone-patient-drug-information\" class=\"drug drug_patient\">see &quot;Mitoxantrone: Patient drug information&quot;</a> and <a href=\"topic.htm?path=mitoxantrone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mitoxantrone: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709094\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Mitoxantrone should be administered under the supervision of a health care provider experienced in the use of cytotoxic chemotherapy agents.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Except for the treatment of acute nonlymphocytic leukemia, mitoxantrone therapy generally should not be given to patients with baseline neutrophil counts of less than 1,500 cells/mm<sup>3</sup>. In order to monitor the occurrence of bone marrow suppression (primarily neutropenia, which may be severe and result in infection), it is recommended that frequent peripheral blood cell counts be performed on all patients receiving mitoxantrone.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Cardiotoxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Congestive heart failure (CHF), potentially fatal, may occur during therapy with mitoxantrone or months to years after termination of therapy. Cardiotoxicity risk increases with cumulative mitoxantrone dose and may occur whether or not cardiac risk factors are present. Presence or history of cardiovascular disease, radiotherapy to the mediastinal/pericardial area, previous therapy with other anthracyclines or anthracenediones, or use of other cardiotoxic drugs may increase this risk. In patients with cancer, the risk of symptomatic CHF was estimated to be 2.6% for patients receiving up to a cumulative dose of 140 mg/m<sup>2</sup>. To mitigate the cardiotoxicity risk with mitoxantrone, consider the following:</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">All patients should be assessed for cardiac signs and symptoms by history, physical examination, and electrocardiogram (ECG) prior to start of mitoxantrone therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">All patients should have baseline quantitative evaluation of left ventricular ejection fraction (LVEF) using appropriate methodology (eg, echocardiogram, multigated radionuclide angiogram [MUGA], magnetic resonance imaging [MRI]).</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with multiple sclerosis (MS) with a baseline LVEF below the lower limit of normal should not be treated with mitoxantrone.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should be assessed for cardiac signs and symptoms by history, physical examination, and ECG prior to each dose.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should undergo quantitative reevaluation of LVEF prior to each dose using the same methodology that was used to assess baseline LVEF. Additional doses of mitoxantrone should not be administered to MS patients who have experienced a drop in LVEF to below the lower limit of normal or a clinically significant reduction in LVEF during mitoxantrone therapy.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should not receive a cumulative mitoxantrone dose higher than 140 mg/m<sup>2</sup>.</p>\n        <p style=\"text-indent:-2em;margin-left:6em;\">Patients with MS should undergo yearly quantitative LVEF evaluation after stopping mitoxantrone to monitor for late-occurring cardiotoxicity.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Secondary leukemia:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-4em;margin-left:4em;\">Mitoxantrone therapy in MS patients and in patients with cancer increases the risk of developing secondary acute myeloid leukemia (AML).</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate administration:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Mitoxantrone should be given slowly into a freely flowing intravenous (IV) infusion. It must never be given subcutaneously, intramuscularly (IM), or intra-arterially. Severe local tissue damage may occur if there is extravasation during administration. Not for intrathecal use. Severe injury with permanent sequelae can result from intrathecal administration.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197570\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Mitoxantrone Injection;</li>\n      <li>Mitoxantrone Injection USP</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197618\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anthracenedione;</li>\n      <li>\n        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197573\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>US labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute nonlymphocytic leukemias (ANLL):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Acute myeloid leukemia (AML) induction:</i> 12 mg/m<sup>2</sup> once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat (7-10 days later) at 12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine) (Arlin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AML consolidation</i> (beginning ~6 weeks after initiation of the final induction course): 12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine), repeat in 4 weeks (Arlin 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Multiple sclerosis:</b> IV: 12 mg/m<sup>2</sup> every 3 months (maximum lifetime cumulative dose: 140 mg/m<sup>2</sup>; discontinue use with LVEF &lt;50% or clinically significant reduction in LVEF)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Prostate cancer (advanced, hormone-refractory):</b> IV: 12 to 14 mg/m<sup>2</sup> every 3 weeks (in combination with corticosteroids)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute nonlymphocytic leukemias (ANLL):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AML induction:</i> 10 to 12 mg/m<sup>2</sup> once daily for 3 days (in combination with cytarabine); for incomplete response, may repeat at 10 to 12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>AML consolidation</i> (beginning ~6 weeks after initiation of the final induction course): 12 mg/m<sup>2</sup> once daily for 2 days (in combination with cytarabine), repeat in 4 weeks</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute leukemias (relapsed): </b> IV: Induction: 12 mg/m<sup>2</sup> once daily for 5 consecutive days; may repeat once if needed (at the same dose and duration)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Breast cancer (metastatic), lymphoma:</b> IV: Initial: Single agent: 14 mg/m<sup>2</sup> every 21 days; reduce initial dose to &le;12 mg/m<sup>2</sup> for myelosuppression due to previous treatment or for poor general health. When used in combination with other agents, reduce initial dose to 10 to 12 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hepatocellular cancer:</b> IV: Initial: Single agent: 14 mg/m<sup>2</sup> every 21 days; reduce initial dose to &le;12 mg/m<sup>2</sup> for myelosuppression due to previous treatment or for poor general health</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>\n        <i>Adult off-label uses and/or dosing:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>AML, refractory:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CLAG-M regimen:</i> 10 mg/m<sup>2</sup> once daily for 3 days (in combination with cladribine, cytarabine, and filgrastim), may repeat once if needed (Wierzbowska 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MEC or EMA regimen:</i> 6 mg/m<sup>2</sup> once daily for 6 days (in combination with cytarabine and etoposide) (Amadori 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Mitoxantrone/Etoposide:</i> 10 mg/m<sup>2</sup> once daily for 5 days (in combination with etoposide) (Ho 1988)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>APL consolidation phase (second course):</b> IV: 10 mg/m<sup>2</sup> once daily for 5 days (Sanz 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hodgkin lymphoma, refractory:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MINE-ESHAP regimen:</i> 10 mg/m<sup>2</sup> on day 1 every 28 days for up to 2 cycles (MINE is combination with mesna, ifosfamide, mitoxantrone, and etoposide; MINE alternates with ESHAP for up to 2 cycles of each) (Fernandez 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>VIM-D regimen:</i> 10 mg/m<sup>2</sup> on day 1 every 28 days (in combination with etoposide, ifosfamide, mesna, and dexamethasone) (Phillips 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Non-Hodgkin lymphoma (as part of combination chemotherapy regimens): </b>IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>CNOP regimen:</i> 10 mg/m<sup>2</sup> every 21 days (Bessell 2003)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>FCMR regimen:</i> 8 mg/m<sup>2</sup> every 28 days (Forstpointner 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>FMR regimen:</i> 10 mg/m<sup>2</sup> every 21 days (Zinzani 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>FND regimen:</i> 10 mg/m<sup>2</sup> every 28 days (Tsimberidou 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>MINE-ESHAP regimen:</i> 8 mg/m<sup>2</sup> every 21 days for 6 cycles (MINE is combination with mesna, ifosfamide, mitoxantrone, and etoposide; followed by ESHAP) (Rodriguez 1995)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Stem cell transplantation, autologous:</b> IV: 60 mg/m<sup>2</sup> administered 4 to 5 days prior to autografting (as 3 divided doses over 1 hour each at 1-2 hour intervals on the same day; in combination with other chemotherapeutic agent[s]) (Oyan 2006; Tarella 2001)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197596\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=mitoxantrone-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Mitoxantrone: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Details concerning dosing in combination regimens should also be consulted.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Acute nonlymphocytic leukemias:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Acute myeloid leukemia (AML) consolidation phase (second course; off-label use):</i> 10 mg/m<sup>2</sup> once daily for 5 days (in combination with cytarabine) (Stevens, 1998) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Acute promyelocytic leukemia (APL) consolidation phase (second course; off-label use):</i> 10 mg/m<sup>2</sup> once daily for 5 days (Ortega, 2005; Sanz, 2004)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197574\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3881589\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">No dosage adjustment provided in manufacturer&rsquo;s labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hemodialysis: Supplemental dose is not necessary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Peritoneal dialysis: Supplemental dose is not necessary </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elderly: Clearance is decreased in elderly patients; use with caution </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197575\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>\n        <i>U.S. labeling:</i></b> No dosage adjustment provided in the manufacturer&rsquo;s labeling; however, clearance is reduced in hepatic dysfunction. Patients with severe hepatic dysfunction (bilirubin &gt;3.4 mg/dL) have an AUC of 3 times greater than patients with normal hepatic function; consider dose adjustments. <b>Note:</b> MS patients with hepatic impairment should not receive mitoxantrone.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>\n        <i>Canadian labeling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Mild-to-moderate impairment: No specific dosage adjustment provided; consider dose adjustments and monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Severe impairment: Use is contraindicated.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20342779\" class=\"block doo drugH1Div\"><span class=\"drugH1\">Dosing: Obesity</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <i>ASCO Guidelines for appropriate chemotherapy dosing in obese adults with cancer: </i> Utilize patient&rsquo;s actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7289331\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>ANLL patients:</b> Severe or life-threatening nonhematologic toxicity: Withhold treatment until toxicity resolves</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">\n      <b>MS patients:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Neutrophils &lt;1500/mm<sup>3</sup>: Use is not recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">Signs/symptoms of HF: Evaluate for cardiac signs/symptoms and LVEF.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">LVEF &lt;50% or baseline LVEF below the lower limit of normal (LLN): Use is not recommended.</p>\n    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;text-align:justify;\">\n      <b>\n        <i>Canadian labeling (not in U.S. labeling): </i></b> <b>Hepatocellular cancer, lymphoma, or breast cancer (metastatic):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC nadir &gt;1500/mm<sup>3</sup> <b>and</b> platelet nadir &gt;50,000/mm<sup>3</sup> and recovery &le;21 days: Repeat previous dose or increase dose by 2 mg/m<sup>2</sup> if myelosuppression is inadequate.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC nadir &gt;1500/mm<sup>3</sup> <b>and</b> platelet nadir &gt;50,000/mm<sup>3</sup> and recovery &gt;21 days: Withhold treatment until recovery then resume at previous dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC nadir &lt;1500/mm<sup>3</sup> <b>or</b> platelet nadir &lt;50,000/mm<sup>3</sup> (regardless of recovery time): Withhold treatment until recovery then decrease previous dose by 2 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">WBC nadir &lt;1000/mm<sup>3</sup> <b>or</b> platelet nadir &lt;25,000/mm<sup>3</sup> (regardless of recovery time): Withhold treatment until recovery then decrease previous dose by 4 mg/m<sup>2</sup>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197544\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Concentrate, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 20 mg/10 mL (10 mL); 25 mg/12.5 mL (12.5 mL); 30 mg/15 mL (15 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197529\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13934999\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">An FDA-approved patient medication guide, which is available with the product information and at <a target=\"_blank\" href=\"http://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn/+Btau8Jzc5BLV85NUiGV68x8FWowpJdF1ZpcexrI9fSA==&amp;TOPIC_ID=9660\" target=\"_blank\">http://www.fda.gov/downloads/Drugs/DrugSafety/UCM297876.pdf</a>, must be dispensed with this medication.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197547\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV administration only; do not administer intrathecally, subcutaneously, intramuscularly or intra-arterially. Must be diluted prior to use. Usually administered as a short IV infusion over 5-15 minutes; do not infuse over &lt;3-5 minutes.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">High doses for bone marrow transplant (off-label use) are usually given as 3 divided doses over 1 hour each at 1-2 hour intervals on the same day (Oyan, 2006; Tarella, 2001).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Irritant with vesicant-like properties; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1-2 days (Perez Fidalgo, 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dexrazoxane:</i> Adults: 1000 mg/m<sup>2</sup> (maximum dose: 2000 mg) IV (administer in a large vein remote from site of extravasation) over 1-2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1000 mg) IV over 1-2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (&plusmn; 3 hours) as the dose on day 1 (Mouridsen, 2007; Perez Fidalgo, 2012). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>DMSO:</i> Children and Adults: Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Perez Fidalgo, 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132772\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197545\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Initial treatment of acute nonlymphocytic leukemias (ANLL [includes myelogenous, promyelocytic, monocytic and erythroid leukemias]); treatment of advanced hormone-refractory prostate cancer; secondary progressive or relapsing-remitting multiple sclerosis (MS)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional uses (not in U.S. labeling): Treatment of metastatic breast cancer, relapsed leukemia (adults), lymphoma, and hepatocellular carcinoma</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25730513\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute lymphocytic leukemia (ALL); Autologous hematopoietic stem cell transplantation (HSCT) (conditioning regimen); Breast cancer (metastatic); Hodgkin lymphoma (refractory); Non-Hodgkin lymphomas (NHL); Pediatric acute myelogenous leukemia (AML); Pediatric acute promyelocytic leukemia (APL); Relapsed acute myeloid leukemia (AML)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197627\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MitoXANTRONE may be confused with methotrexate, mitoMYcin, mitotane, Mutamycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197536\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Includes events reported with any indication; incidence varies based on treatment, dose, and/or concomitant medications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Edema (10% to 30%), cardiac disease (&le;18%), cardiac arrhythmia (3% to 18%), ECG changes (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Pain (8% to 41%), fatigue (&le;39%), headache (6% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (20% to 61%), nail bed changes (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Menstrual disease (26% to 61%), amenorrhea (28% to 53%), hyperglycemia (10% to 31%), weight gain (&le;17%), weight loss (&le;17%), increased gamma-glutamyl transferase (3% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (26% to 76%), vomiting (6% to 72%), diarrhea (14% to 47%), mucositis (10% to 29%; onset: &le;1 week), stomatitis (8% to 29%; onset: &le;1 week), anorexia (22% to 25%), constipation (10% to 16%), gastrointestinal hemorrhage (2% to 16%), abdominal pain (9% to 15%), dyspepsia (5% to 14%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urinary tract infection (7% to 32%), hematuria (&le;11%), urine abnormality (5% to 11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Neutropenia (79% to 100%; onset: &le;3 weeks; grade 4: 23% to 54%), leukopenia (9% to 100%), lymphocytopenia (72% to 95%), anemia (&le;75%), decreased hemoglobin (&le;75%), thrombocytopenia (33% to 39%; grades 3/4: 3% to 4%), bruise (&le;11%), febrile neutropenia (&le;11%), petechia (&le;11%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum alkaline phosphatase (&le;37%), increased serum transaminases (5% to 20%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (4% to 60%), sepsis (&le;34%), fungal infection (9% to 15%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Weakness (&le;24%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Increased blood urea nitrogen (&le;22%), increased serum creatinine (&le;13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Upper respiratory tract infection (7% to 53%), pharyngitis (&le;19%), dyspnea (6% to 18%), cough (5% to 13%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (6% to 78%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (&le;5%), ischemia (&le;5%), decreased left ventricular ejection fraction (&le;5%), hypertension (&le;4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Chills (&le;5%), anxiety (5%), depression (5%), seizure (2% to 4%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&le;9%), skin infection (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypocalcemia (10%), hypokalemia (7% to 10%), hyponatremia (9%), hypermenorrhea (7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Aphthous stomatitis (&le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Impotence (&le;7%), proteinuria (&le;6%), sterility (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Granulocytopenia (6%), hemorrhage (5% to 6%), acute leukemia (&le;3%; secondary; includes AML, APL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Jaundice (3% to 7%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Fungal infection (cutaneous: &le;10%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Back pain (6% to 8%), arthralgia (&le;5%), myalgia (&le;5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Conjunctivitis (&le;5%), blurred vision (&le;3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal failure (&le;8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Rhinitis (10%), pneumonia (&le;9%), sinusitis (&le;6%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Anaphylactoid reaction, anaphylaxis, chest pain, dehydration, hypersensitivity reaction, interstitial pneumonitis (with combination chemotherapy), hyperuricemia, hypotension, ocular discoloration (blue discoloration of sclera), phlebitis (at infusion site), skin rash, tachycardia, urine discoloration (blue-green), urticaria</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197550\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to mitoxantrone or any component of the formulation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in U.S. labeling): Prior hypersensitivity to anthracyclines; prior substantial anthracycline exposure and abnormal cardiac function prior to initiation of mitoxantrone therapy; presence of severe myelosuppression due to prior chemo- and/or radiotherapy; severe hepatic impairment; intrathecal administration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197533\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Treatment may lead to severe myelosuppression; unless the expected benefit outweighs the risk, use is generally not recommended in patients with pre-existing myelosuppression from prior chemotherapy. <b>[U.S. Boxed Warning]: Usually should not be administered if baseline neutrophil count &lt;1500 cells/mm<sup>3</sup> (except for in the treatment of ANLL). Monitor blood counts and monitor for infection due to neutropenia.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Extravasation: Irritant with vesicant-like properties. <b>[U.S. Boxed Warning]: For IV administration only, into a free-flowing IV; may cause severe local tissue damage if extravasation occurs. </b>Extravasation resulting in burning, erythema, pain, swelling and skin discoloration (blue) has been reported; may result in tissue necrosis and require debridement for skin graft. Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperuricemia: Rapid lysis of tumor cells may lead to hyperuricemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Myocardial toxicity: <b>[U.S. Boxed Warning]: May cause myocardial toxicity and potentially-fatal heart failure (HF); risk increases with cumulative dosing. Effects may occur during therapy or may be delayed (months or years after completion of therapy). Predisposing factors for mitoxantrone-induced cardiotoxicity include prior anthracycline or anthracenedione therapy, prior cardiovascular disease, concomitant use of cardiotoxic drugs, and mediastinal/pericardial irradiation, although may also occur in patients without risk factors. Prior to therapy initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; and evaluate baseline left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. Not recommended for use in MS patients when LVEF &lt;50%, or baseline LVEF below the lower limit of normal (LLN). Evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) in MS patients prior to each dose and if signs/symptoms of HF develop. Use in MS should be limited to a cumulative dose of &le;140 mg/m<sup>2</sup>, and discontinued if LVEF falls below LLN or a significant decrease in LVEF is observed; decreases in LVEF and HF have been observed in patients with MS who have received cumulative doses &lt;100 mg/m<sup>2</sup>. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Secondary malignancy: <b>[U.S. Boxed Warning]: Treatment with mitoxantrone increases the risk of developing secondary acute myelogenous leukemia (AML) in patients with cancer and in patients with MS;</b> acute promyelocytic leukemia (APL) has also been observed. Symptoms of acute leukemia include excessive bruising, bleeding and recurrent infections. The risk for secondary leukemia is increased in patients who are heavily pretreated, with higher doses, and with combination chemotherapy.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Clearance is reduced in patients with hepatic impairment; use with caution; dosage adjustment recommended. Not for treatment of multiple sclerosis in patients with concurrent hepatic impairment. Canadian labeling contraindicates use in severe impairment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Multiple sclerosis: Not for treatment of primary progressive multiple sclerosis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate administration: <b>[U.S. Boxed Warning]: For IV administration only, into a free-flowing IV; do not administer subcutaneously, intramuscularly, or intra-arterially. Do not administer intrathecally; may cause serious and permanent neurologic damage.</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Blue-green coloration: May cause urine, saliva, tears, and sweat to turn blue-green for 24 hours postinfusion; whites of eyes may have blue-green tinge. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[U.S. Boxed Warning]: Should be administered under the supervision of a physician experienced in cancer chemotherapy agents.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197613\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of BCRP/ABCG2</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197538\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9660&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): May increase the serum concentration of MitoXANTRONE. Management: Consider mitoxantrone dose reduction, as clinically appropriate, when used with cyclosporine. Use this combination with caution and monitor closely for toxic effects of mitoxantrone.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197540\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">D (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197553\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have been observed in animal reproduction studies. Based on the mechanism of action, mitoxantrone may cause fetal harm if administered during pregnancy. Use of effective contraception during therapy is recommended. Information related to pregnancy outcomes following maternal use of mitoxantrone in pregnancy is limited (Amato 2015; Houtchens 2013; NTP 2013). </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Infertility and amenorrhea have been reported in women with MS using mitoxantrone (Amato 2015; Houtchens 2013). Women with multiple sclerosis who are of reproductive potential should have a pregnancy test prior to each dose. Women who wish to become pregnant should discontinue therapy at least 2 to 3 months prior to conception (Houtchens 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The European Society for Medical Oncology has published guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy. The guidelines recommend referral to a facility with expertise in cancer during pregnancy and encourage a multidisciplinary team (obstetrician, neonatologist, oncology team). In general, if chemotherapy is indicated, it should be avoided in the first trimester, there should be a 3-week time period between the last chemotherapy dose and anticipated delivery, and chemotherapy should not be administered beyond week 33 of gestation (Peccatori 2013). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197554\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Mitoxantrone is excreted in human milk and significant concentrations (18 ng/mL) have been reported for 28 days after the last administration. Due to the potential for serious adverse reactions in the nursing infant, the manufacturer recommends that breast-feeding be discontinued before starting treatment. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197542\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential, serum uric acid (for leukemia treatment), liver function tests; for the treatment of multiple sclerosis, obtain pregnancy test; monitor injection site for extravasation</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <i>Cardiac monitoring:</i> Prior to initiation, evaluate all patients for cardiac-related signs/symptoms, including history, physical exam, and ECG; evaluate baseline and periodic left ventricular ejection fraction (LVEF) with echocardiogram or multigated radionuclide angiography (MUGA) or MRI. In patients with MS, evaluate for cardiac signs/symptoms (by history, physical exam, and ECG) and evaluate LVEF (using same method as baseline LVEF) prior to each dose and if signs/symptoms of HF develop. Patients with MS should undergo annual LVEF evaluation following discontinuation of therapy to monitor for delayed cardiotoxicity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197532\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Related to the anthracyclines, mitoxantrone intercalates into DNA resulting in cross-links and strand breaks; binds to nucleic acids and inhibits DNA and RNA synthesis by template disordering and steric obstruction; replication is decreased by binding to DNA topoisomerase II and seems to inhibit the incorporation of uridine into RNA and thymidine into DNA; active throughout entire cell cycle (cell-cycle nonspecific)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197549\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Oral: Poor </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: 14 L/kg; V<sub>dss</sub>: &gt;1,000 L/m<sup>2</sup>; distributes extensively into pleural fluid, kidney, thyroid, liver, heart, pancreas, spleen, bone marrow, and red blood cells; prolonged retention in tissues</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 78% </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Hepatic; pathway not determined </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: 23 to 215 hours (median: ~75 hours); may be prolonged with hepatic impairment </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Feces (25%); urine (6% to 11%; 65% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323431\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Concentrate</b> (MitoXANTRONE HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/10 mL (10 mL): $303.53</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">25 mg/12.5 mL (12.5 mL): $324.71</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">30 mg/15 mL (15 mL): $409.42</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F197555\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bluxantron (EC);</li>\n      <li>Bresnix (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Domitrone (PH);</li>\n      <li>Ebexantron (SG);</li>\n      <li>Elsep (FR);</li>\n      <li>Evomixan (BR);</li>\n      <li>Formyxan (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Heng En (CN);</li>\n      <li>Mi Xi Ning (CN);</li>\n      <li>Misostol (PY, VE);</li>\n      <li>Mitoxgen (AR, MX);</li>\n      <li>Mitroxone (MX);</li>\n      <li>Mittrone (KR);</li>\n      <li>Neotalem (CL, CO, TH);</li>\n      <li>Novantron (AT, CH, DE);</li>\n      <li>Novantrone (AE, BE, CN, DK, EG, ES, FI, FR, GB, GR, HR, HU, IL, IT, JO, JP, KW, LU, NL, NO, NZ, PK, PL, PT, RO, RU, SA, SE, TR, TW, VN);</li>\n      <li>Oncotron (IN);</li>\n      <li>Oncotrone (BG);</li>\n      <li>Onkotron (UA);</li>\n      <li>Onkotrone (AU, EE, HU, LT, LV, NZ, RO, SI, SK);</li>\n      <li>Refador (CZ);</li>\n      <li>Santrone (HK);</li>\n      <li>Strimax (MT);</li>\n      <li>Vizksantron (UA)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Amadori S, Arcese W, Isacchi G, et al, &ldquo;Mitoxantrone, Etoposide, and Intermediate-Dose Cytarabine: An Effective and Tolerable Regimen for the Treatment of Refractory Acute Myeloid Leukemia,&rdquo; <i>J Clin Oncol</i>, 1991, 9(7):1210-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2045861/pubmed\" target=\"_blank\" id=\"2045861\">2045861</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Amato MP, Portaccio E. Fertility, pregnancy and childbirth in patients with multiple sclerosis: impact of disease-modifying drugs. <i>CNS Drugs</i>. 2015;29(3):207-220.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/25773609 /pubmed\" target=\"_blank\" id=\"25773609 \">25773609 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Arlin Z, Case DC Jr, Moore J, et al, &ldquo;Randomized Multicenter Trial of Cytosine Arabinoside With Mitoxantrone or Daunorubicin in Previously Untreated Adult Patients With Acute Nonlymphocytic Leukemia (ANLL). Lederle Cooperative Group,&rdquo; <i>Leukemia</i>, 1990, 4(3):177-83.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2179638/pubmed\" target=\"_blank\" id=\"2179638\">2179638</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. <i>J Clin Oncol</i>. 2014;32(30):3436-3448.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/25199761/pubmed\" target=\"_blank\" id=\"25199761\">25199761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bessell EM, Burton A, Haynes AP, et al, &ldquo;A Randomised Multicentre Trial of Modified CHOP Versus MCOP in Patients Aged 65 Years and Over With Aggressive Non-Hodgkin's Lymphoma, <i>Ann Oncol</i>, 2003, 14(2):258-67.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/12562653/pubmed\" target=\"_blank\" id=\"12562653\">12562653</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Donelli MG,  Zuchetti M, Munzone E, et al, &ldquo;Pharmacokinetics of Anticancer Agents in Patients With Impaired Liver Function,&rdquo; <i>Eur J Cancer,</i> 1998, 34(1):33-46.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/9624235/pubmed\" target=\"_blank\" id=\"9624235\">9624235</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ehninger G, Schuler U, Proksch B, et al, &quot;Pharmacokinetics and Metabolism of Mitoxantrone. A Review,&quot;<i>Clin Pharmacokinet</i>, 1990, 18(5):365-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2185907/pubmed\" target=\"_blank\" id=\"2185907\">2185907</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Faulds D, Balfour JA, Chrisp P, et al, &ldquo;Mitoxantrone. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in the Chemotherapy of Cancer,&rdquo; <i>Drugs</i>, 1991, 41(3):400-49. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/1711446/pubmed\" target=\"_blank\" id=\"1711446\">1711446</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fernandex de Larrea C, Martinez C, Gaya A, et al, &ldquo;Salvage Chemotherapy With Alternating MINE-ESHAP Regimen in Relapsed or Refractory Hodgkin&rsquo;s Lymphoma Followed By Autologous Stem-Cell Transplantation,&rdquo; <i>Ann Oncol</i>, 2010, 21(6):1211-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19889622/pubmed\" target=\"_blank\" id=\"19889622\">19889622</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Forstpointner R, Dreyling M, Repp R, et al, &ldquo;The Addition of Rituximab to a Combination of Fludarabine, Cyclophosphamide, Mitoxantrone (FCM) Significantly Increases the Response Rate and Prolongs Survival as Compared With FCM Alone in Patients With Relapsed and Refractory Follicular and Mantle Cell Lymphomas: Results of a Prospective Randomized Study of the German Low-Grade Lymphoma Study Group,&rdquo; <i>Blood</i>, 2004, 104(10):3064-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15284112/pubmed\" target=\"_blank\" id=\"15284112\">15284112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Henderson IC, Allegra JC, Woodcock T, et al, &ldquo;Randomized Clinical Trial Comparing Mitoxantrone With Doxorubicin in Previously Treated Patients With Metastatic Breast Cancer,&rdquo; <i>J Clin Oncol</i>, 1989, 7(5):560-71.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2468745/pubmed\" target=\"_blank\" id=\"2468745\">2468745</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ho AD, Lipp T, Ehninger G, et al, &ldquo;Combination of Mitoxantrone and Etoposide in Refractory Acute Myelogenous Leukemia an Active and Well-Tolerated Regimen,&rdquo; <i>J Clin Oncol</i>, 1988, 6(2):213-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/3422260 /pubmed\" target=\"_blank\" id=\"3422260 \">3422260 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. <i>J Neurol</i>. 2013;260(5):1202-1214.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/22926165/pubmed\" target=\"_blank\" id=\"22926165\">22926165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jeffrey LP, Chairman, National Study Commission on Cytotoxic Exposure. Position Statement. &ldquo;The Handling of Cytotoxic Agents by Women Who Are Pregnant, Attempting to Conceive, or Breast-Feeding,&rdquo; January 12, 1987. </div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mandelli F, Vignetti M, Suciu S, et al, &ldquo;Daunorubicin versus Mitoxantrone versus Idarubicin as Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10,&rdquo;  <i>J Clin Oncol</i>, 2009, 27(32):5397-403.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19826132/pubmed\" target=\"_blank\" id=\"19826132\">19826132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouridsen HT, Langer SW, Buter J, et al, &ldquo;Treatment of Anthracycline Extravasation With Savene (Dexrazoxane): Results From Two Prospective Clinical Multicentre Studies,&rdquo; <i>Ann Oncol</i>, 2007, 18(3):546-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/17185744/pubmed\" target=\"_blank\" id=\"17185744\">17185744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    National Toxicology Program (NTP) Monograph on Developmental Effects and Pregnancy Outcomes Associated with Cancer Chemotherapy Use during Pregnancy, May 2013. Available at <a href=\"http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html\" target=\"_blank\">http://ntp.niehs.nih.gov/pubhealth/hat/noms/chemo/index.html</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Novantrone (mitoxantrone) [prescribing information]. Rockland, MA: Serono; May 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ortega JJ, Madero L, Martin G, et al, &ldquo;Treatment With All-<i>Trans</i> Retinoic Acid and Anthracycline Monochemotherapy for Children With Acute Promyelocytic Leukemia: A Multicenter Study by the PETHEMA Group,&rdquo; <i>J Clin Oncol</i>, 2005, 23(30):7632-40. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/16234524/pubmed\" target=\"_blank\" id=\"16234524\">16234524</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Oyan B, Koc Y, Ozdemir E, et al, &ldquo;High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in Patients With Relapsed/Refractory Lymphoma,&rdquo; <i>Leuk Lymphoma</i>, 2006, 47(8):1545-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/16966265/pubmed\" target=\"_blank\" id=\"16966265\">16966265</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24 Suppl 6:vi160-167.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/23813932 /pubmed\" target=\"_blank\" id=\"23813932 \">23813932 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al, &ldquo;Management of Chemotherapy Extravasation: ESMO-EONS Clinical Practice Guidelines,&rdquo; <i>Ann Oncol</i>, 2012, 23(Suppl 7):167-73.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petrylak DP, Tangen CM, Hussain MH, et al, &ldquo;Docetaxel and Estramustine Compared With Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer,&rdquo; <i>N Engl J Med</i>, 2004, 351(15):1513-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15470214/pubmed\" target=\"_blank\" id=\"15470214\">15470214</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Phillips JK, Spearing RL, Davies JM, et al, &ldquo;VIM-D Salvage Chemotherapy in Hodgkin's Disease,&rdquo; <i>Cancer Chemother Pharmacol</i>, 1990, 27(2):161-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/2249334/pubmed\" target=\"_blank\" id=\"2249334\">2249334</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pratt CB, Vietti TJ, Etcubanas E, et al, &ldquo;Novantrone&reg; for Childhood Malignant Solid Tumors. A Pediatric Oncology Group Phase II Study,&rdquo; <i>Invest New Drugs</i>, 1986, 4(1):43-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/3700039/pubmed\" target=\"_blank\" id=\"3700039\">3700039</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rodriguez MA, Cabanillas FC, Velasquez W, et al, &ldquo;Results of a Salvage Treatment Program for Relapsing Lymphoma: MINE Consolidated With ESHAP,&rdquo; <i>J Clin Oncol</i>, 1995, 13(7):1734-41.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/602363/pubmed\" target=\"_blank\" id=\"602363\">602363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Martin G, Gonzalez M, et al, &ldquo;Risk-Adapted Treatment of Acute Promyelocytic Leukemia With All-<i>Trans</i>-Retinoic Acid and Anthracycline Monochemotherapy: A Multicenter Study by the PETHEMA Group,&rdquo; <i>Blood</i>, 2004, 103(4):1237-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/14576047/pubmed\" target=\"_blank\" id=\"14576047\">14576047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Scott LJ and Figgitt DP, &quot;Mitoxantrone: A Review of its Use in Multiple Sclerosis,&quot; <i>CNS Drugs</i>, 2004, 18(6):379-96.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15089110/pubmed\" target=\"_blank\" id=\"15089110\">15089110</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Stevens RF, Hann IM, Wheatley K, et al, &ldquo;Marked Improvements in Outcome With Chemotherapy Alone in Paediatric Acute Myeloid Leukemia: Results of the United Kingdom Medical Research Council's 10th AML Trial: MRC Childhood Leukaemia Working Party,&rdquo; <i>Br J Haematol</i>, 1998, 101(1):130-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/9576193/pubmed\" target=\"_blank\" id=\"9576193\">9576193</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tannock IF, de Wit R, Berry WR, et al, &ldquo;Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer,&rdquo; <i>N Engl J Med</i>, 2004, 351(15):1502-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15470213/pubmed\" target=\"_blank\" id=\"15470213\">15470213</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tarella C, Zallio F, Caracciolo D, et al, &ldquo;High-Dose Mitoxantrone + Melphalan (MITO/L-PAM) as Conditioning Regimen Supported by Peripheral Blood Progenitor Cell (PBPC) Autograft in 113 Lymphoma Patients: High Tolerability With Reversible Cardiotoxicity,&rdquo; <i>Leukemia</i>, 2001, 15(2):256-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/11236941/pubmed\" target=\"_blank\" id=\"11236941\">11236941</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Toledano A, Azria D, Garaud P, et al, &ldquo;Phase III Trial of Concurrent or Sequential Adjuvant Chemoradiotherapy After Conservative Surgery for Early-Stage Breast Cancer: Final Results of the ARCOSEIN Trial,&rdquo; <i>J Clin Oncol</i>, 2007, 25(4):405-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/17264336/pubmed\" target=\"_blank\" id=\"17264336\">17264336</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsimberidou AM, McLaughlin P, Younes A, et al, &ldquo;Fludarabine, Mitoxantrone, Dexamethasone (FND) Compared With an Alternating Triple Therapy (ATT) Regimen in Patients With Stage IV Indolent Lymphoma,&rdquo; <i>Blood</i>, 2002, 100(13):4351-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/12393618/pubmed\" target=\"_blank\" id=\"12393618\">12393618</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vitolo U, Chiappella A, Angelucci E, et al, &ldquo;Dose-Dense and High-Dose Chemotherapy Plus Rituximab With Autologous Stem Cell Transplantation for Primary Treatment of Diffuse Large B-Cell Lymphoma With a Poor Prognosis: A Phase II Multicenter Study,&rdquo; <i>Haematologica</i>, 2009, 94(9):1250-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/19586937/pubmed\" target=\"_blank\" id=\"19586937\">19586937</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Weiss M, Maslak P, Feldman E, et al, &ldquo;Cytarabine With High-Dose Mitoxantrone Induces Rapid Complete Remissions in Adult Acute Lymphoblastic Leukemia Without the Use of Vincristine or Prednisone,&rdquo; <i>J Clin Oncol</i>, 1996, 14(9):2480-5.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/8823326/pubmed\" target=\"_blank\" id=\"8823326\">8823326</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wierzbowska A, Robak T, Pluta A, et al, &ldquo;Cladribine Combined With High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) is a Highly Effective Salvage Regimen in Patients With Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group,&rdquo; <i>Eur J Haematol</i> 2008; 80(2):115-26.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/18076637/pubmed\" target=\"_blank\" id=\"18076637\">18076637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinzani PL, Pulsoni A, Perrotti A, et al, &ldquo;Fludarabine Plus Mitoxantrone With and Without Rituximab Versus CHOP With and Without Rituximab as Front-Line Treatment for Patients With Follicular Lymphoma,&rdquo; <i>J Clin Oncol</i>, 2004, 22(13):2654-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/15159414/pubmed\" target=\"_blank\" id=\"15159414\">15159414</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zinzani PL, Tani M, Pulsoni A, et al, &ldquo;Fludarabine and Mitoxantrone Followed by Yttrium-90 Ibritumomab Tiuxetan in Previously Untreated Patients With Follicular Non-Hodgkin Lymphoma Trial: A Phase II Non-Randomised Trial (FLUMIZ),&rdquo; <i>Lancet Oncol</i>, 2008, 9(4):352-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/mitoxantrone-drug-information/abstract-text/18342572/pubmed\" target=\"_blank\" id=\"18342572\">18342572</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9660 Version 158.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709094\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F197570\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F197618\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F197573\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F197596\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F197574\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F3881589\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F197575\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Obesity\" href=\"#F20342779\" class=\"outlineLink\">Dosing: Obesity</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F7289331\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F197544\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F197529\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F13934999\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F197547\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132772\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F197545\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25730513\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F197627\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F197536\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F197550\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F197533\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F197613\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F197538\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F197540\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F197553\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F197554\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F197542\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F197532\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F197549\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323431\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F197555\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9660|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=mitoxantrone-patient-drug-information\" class=\"drug drug_patient\">Mitoxantrone: Patient drug information</a></li><li><a href=\"topic.htm?path=mitoxantrone-pediatric-drug-information\" class=\"drug drug_pediatric\">Mitoxantrone: Pediatric drug information</a></li></ul></div></div>","javascript":null}